Vaniprevir
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) NS3/4A protease inhibitor, developed by Merck & Co., which is currently in clinical testing.[1]
Names | |
---|---|
IUPAC name
(1R,21S,24S)-21-tert-Butyl-N-((1R,2R)-1-{[(cyclopropylsulfonyl)amino]carbonyl}-2-ethylcyclopropyl)-16,16-dimethyl-3,19,22-trioxo-2,18-dioxa-4,20,23-triazatetracyclo[21.2.1.14,7.06,11]-heptacosa-6,8,10-triene-24-carboxamide | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.207.830 |
EC Number |
|
KEGG | |
PubChem CID |
|
UNII | |
InChI
| |
SMILES
| |
Properties | |
Chemical formula |
C38H55N5O9S |
Molar mass | 757.94 g·mol−1 |
Appearance | White powder |
Hazards | |
GHS labelling: | |
Pictograms |
|
Signal word |
Warning |
Hazard statements |
H373 |
Precautionary statements |
P260, P314, P501 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
In Japan, it was approved for treating hepatitis C in 2014 under the brand name Vanihep.[2][3]
References
- McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ (March 2010). "Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor". J. Med. Chem. 53 (6): 2443–63. doi:10.1021/jm9015526. PMID 20163176.
- "First recommendation for HCV drug vaniprevir, in Japan". datamonitorhealthcare.com. September 25, 2014.
- "New Drugs Approved" (PDF). Pharmaceuticals and Medical Devices Agency.
{{cite journal}}
: Cite journal requires|journal=
(help)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.